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Abstract: The topic of early response to antidepressant treatment has been extensively studied in major depressive disor-
der (MDD). We serendipitous observed an increase tolerability, a rapid response to therapy and an early onset of antide-
pressant fluvoxamine activity when associated with amisulpride in patients with major depressive disorder. The purpose 
of this study was to investigate our preliminary observations.  
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INTRODUCTION  
One of the principal stakes of depression treatment are to 
accelerate and enhance the clinical effects of antidepressant 
drug [1].  
The development of selective serotonin reuptake inhibi-
tors (SSRIs) provided a major advancement in the treatment 
of depression. However, these drugs suffer from a variety of 
drawbacks, most notably a delay in the onset of efficacy [2].  
The delay in the response of SSRIs has been investigated 
both in the field of clinical and preclinical research.  
According to main observations [3, 4] the onset of action 
with SSRI agents depends on the activation of the 5HT-1A 
autoreceptors, which one tries to hinder by using drugs able 
to operate a selective blockade [5].  
Although SSRIs block serotonin (5-hydroxytryptamine, 
5-HT) reuptake rapidly, their therapeutic action is delayed. 
One hypothesis suggests that this delay in efficacy is due to a 
paradoxical decrease in serotonergic (5-HT) neuronal im-
pulse flow and release, following activation of inhibitory 
presynaptic 5-HT1A autoreceptors, following acute admini-
stration of SSRIs. According to the hypothesis, efficacy is 
seen only when this impulse flow is restored following de-
sensitization of 5-HT1A autoreceptors and coincident in-
creases in postsynaptic 5-HT levels are achieved [2].  
The onset of antidepressant action of SSRIs was attrib-
uted in part to this decrease in firing activity of serotonin 
neurons produced by the activation of raphe 5HT1A autore-
ceptors at the time of treatment initiation [1, 6, 7].  
The increase in synaptic 5-HT activates feedback mecha-
nisms mediated by 5-HT1A (cell body) and 5-HT1B (termi-
nal) autoreceptors, which, respectively, reduce the firing in 
5-HT neurons and decrease the amount of 5-HT released per 
action potential resulting in attenuated 5-HT neurotransmis- 
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sion. Long-term treatment desensitizes the inhibitory 5-HT1 
autoreceptors, and 5-HT neurotransmission is enhanced. The 
time course of these events is similar to the delay of clinical 
action [8].  
Clinical proof of this principal has been suggested in 
studies that found a significant augmenting effect when the 
beta-adrenergic/5-HT1A receptor antagonist was co-
administered with SSRI treatment [2, 9].  
Pindolol, an antagonist at somatodendritic pre-synaptic 
5HT1A receptors has been investigated as a potential accel-
erator or potentialisator of antidepressant response [1].  
The addition of pindolol, which blocks 5-HT1A recep-
tors, to SSRI treatment decouples the feedback inhibition of 
5-HT neuron firing and accelerates and enhances the antide-
pressant response [6, 7].  
The neuronal circuitry of the 5-HT and norepinephrine 
(NE) systems and their connections to forebrain areas be-
lieved to be involved in depression has been dissected. The 
firing of 5-HT neurons in the raphe nuclei is driven, at least 
partly, by alpha1-adrenoceptor-mediated excitatory inputs 
from NE neurons. Inhibitory alpha2-adrenoceptors on the 
NE neuroterminals form part of a feedback control mecha-
nism [10].  
Results indicate that (-)pindolol potentiated the activation 
of postsynaptic 5-HT(1A) receptors resulting from 5-HT 
reuptake inhibition probably by blocking the somatodendritic 
5-HT(1A) autoreceptor, but not its postsynaptic congener. 
These results support and extend previous findings providing 
a biological substratum for the efficacy of pindolol as an 
accelerating strategy in major depression [11].  
In any case how such drugs as pindolol actually work is 
still controversial [12-14].  
Gartside et al. have suggested that both (-)-tertatolol and 
(-)-penbutolol are superior to (+/-)pindolol in terms of en-
hancing the effect of an SSRI on extracellular 5-HT [9].  
We serendipitous observed in patients with both 
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with others presenting only major depressive disorder a de-
creased latency period in the action of SSRI when associated 
with amisulpride [15].  
We therefore planned a large open trial with the concur-
rent administration of SSRI fluvoxamine, as a base antide-
pressant, and substituted benzamide amisulpride.  
Although antidepressant medications are effective in 
about 50-70% of patients with major depressive disorder 
(MDD), they have a delayed onset of therapeutic effect. This 
latency on the onset of action is one of the current major 
limitations of these medications, in that it prolongs the im-
pairments associated with depression, leaves patients vulner-
able to an increased risk of suicide, increases the likelihood 
that a patient will prematurely discontinue therapy, and in-
creases medical costs associated with severe depression [16].  
SSRIs are increasingly used in the treatment of depres-
sion [17]. They have efficacy limitations, such as a 2-to 4-
week delay before the onset of symptom relief. They are 
well tolerated. The most frequently reported adverse event is 
nausea [18].  
The use of SSRIs was suggested by the evaluation of 
large double-blind, randomized, controlled trials outlining 
fluvoxamine as effective as other SSRIs, but endowed with 
shorter therapeutic latency [19] and an earlier onset of its 
action when associated with pindolol rather than de-
sipramine, thus proving ideal in the search of an optimized 
latency period.  
The dopaminergic antidepressant action of substituted 
benzamides has been proposed, since the late 1970s, by sev-
eral authors and extensively explored in preclinical experi-
ments [20]. The class of substituted benzamides includes 
compounds able to modulate dopaminergic neurons selec-
tively and specifically. The first synthetic substituted ben-
zamide was sulpiride, which has been replaced in the clinic 
by the more modern amisulpride [21]. In Italy, the first mar-
keting authorization obtained for the amisulpride, was with 
the sole indication of dysthymia and therefore a solid clinical 
experience exists in the use of substituted benzamides in 
mild forms of depression. Amisulpride is a substituted ben-
zamide that, at low doses, selectively blocks D2 and D3 pre-
synaptic dopamine receptors, enhancing dopaminergic 
transmission in frontal cortex and limbic areas. Many clini-
cal studies versus placebo, tricyclic antidepressants and se-
lective serotonin reuptake inhibitors showed amisulpride 
antidepressant effect, supporting its safety and rapid onset of 
action [22]. The proposed mechanism of action of substi-
tuted benzamides implies a selective modulation of the do-
paminergic system in the mesocorticolimbic area, important 
for cognitive processing of internal and external cues, related 
to survival [20]. The compound is very selective for 
mesolimbic D2 and D3 receptors and, therefore, has a dual 
mechanism of action, which is associated with two different 
indications. At low doses (50 mg), amisulpride preferentially 
blocks presynaptic autoreceptors, producing an increase in 
dopamine release, and therefore acting as a dopaminergic 
compound able to resolve the dopaminergic hypoactivity that 
characterizes depression. At higher doses (400-1.200 mg), 
the drug exerts its activity on postsynaptic D3/D2 receptors 
located in the limbic region and prefrontal areas, producing 
selective dopaminergic inhibition, eliciting antipsychotic 
effects. Based on experimental data, amisulpride is a treat-
ment of choice for dopaminergic transmission disorders, 
both in depression and in schizophrenia [21].  
MATERIALS AND METHODS  
A trial carried out on 20 women (mean age 51.3 years) 
with DSM-IV TR [23] diagnostic criteria for major depres-
sive disorder and a Hamilton Depression Rating Scale 
(HDRS) [24-26] score higher than 20.  
Exclusion factor was the age under 35 years.  
Each patient was given fluvoxamine (100mg/day) and 
amisulpride (50mg/day) throughout the 6week trial.  
Clinical symptoms were evaluated by using Hamilton 
Depression Rating Scale (HDRS) [24-26] at the end of week 
1, 2, 3, 6.  
RESULTS  
HDRS score at baseline was 26.2±5.2 and at the end of 
the trial the mean score was 9.6±3.8. At the end of the week-
6 only one patient presented a HDRS score higher than 20.  
The ANOVA one way for repeated measures carried out 
on the basis of the HDRS score at baseline and at week 1, 2, 
3 and 6 stage expressed a statistically significant improve-
ment of depressive symptoms (F=4.5; DF 19,80,4,76,99; P < 
0.00001). Table 1 shows the HDRS scores at the different 
evaluations of the trial.  
The difference of the HDRS score reached the statisti-
cally significance between baseline and week 1 and then 
progressively increased.  
Nineteen patients showed a clear improvement of depres-
sive symptoms between the day 0 and 14. The HDRS item 
analysis demonstrated that the first therapeutic effect was the 
disappearance of the sleep depressive pattern. This effect 
was clear in 10 patients at the end of the first week.  
None of the patients expressed significant side effects. 
Two patients complained excessive drowsiness.  
CONCLUSION  
Though methodologically limited (short sample and open 
trial) the study appears to suggest an increased SSRI toler-
ability (absence of nausea and vomiting) and a shorter la-
tency period.  
The first information is not surprising, considering the 
peculiar fluvoxamine and SSRI side effects related to gastric 
functions and nausea and the specific anti-nausea action of 
substituted benzamides.  
On the other hand the earlier onset of SSRI activity de-
fies easy interpretation. It is however important to remember 
that depressive symptomatology, at least in some cases, is 
mediated by final dopaminergic pathways, on which sero-
toninergic and adrenergic intermediate carriers may interfere 
[27].  
The early onset of action on depressive sleep pointed out 
by this study seems to have a relationship (and to some ex-
tent seems to confirm) with a specific fluvoxamine effect on 
the sleep depressive pattern. This action appears to be a 
characteristic of this drug in comparison with other SSRIs 
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Adjunctive amisulpride to fluvoxamine indicate that they 
may be a potential strategy for an early onset of SSRI activ-
ity in the treatment of major depressive disorder. Further and 
more detailed reports are necessary to confirm these find-
ings.  
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Table 1. Hamilton Depression Rating Scale Scores at the Different Evaluations During the Trial 
Stage of Trial  HDRS Score  SD 
F ANOVA 
Vs T0 (DF 1,38,39) 
P 
To 26.2 2.9     
T1 21.9 5.4 9.38  0.003 
T2 16.1  13.4  10.38  0.002 
T3 13.4 3.9  138.7  <0.0001 
T6 9.6 3.8  235.4  <0.0001 